{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:05:43Z","timestamp":1784009143216,"version":"3.55.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Colorectal cancer (CRC) with microsatellite-stable (MSS)\/pMMR status resists immune checkpoint blockade due to its immunologically \u201ccold\u201d tumor microenvironment. We developed Lipo-LPS-Rg3, a dual-functional nanoliposome co-delivering lipopolysaccharide (LPS) and ginsenoside Rg3, to simultaneously ignite pyroptosis and attenuate PD-L1-associated immune suppression. LPS triggered GSDMD-mediated pyroptosis, releasing DAMPs and recruiting CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, while Rg3 reduced PD-L1 expression\n                    <jats:italic>in vitro<\/jats:italic>\n                    , at least partly by inhibiting NFATc1 nuclear translocation.\n                    <jats:italic>In vivo<\/jats:italic>\n                    , Lipo-LPS-Rg3 decreased PD-L1 protein expression in tumor tissues and promoted both CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cell infiltration and IFN-\u03b3-producing effector function. The nanoplatform achieved tumor-targeted delivery, induced near-complete regression in colorectal cancer, and exhibited minimal systemic toxicity. By converting \u201ccold\u201d tumors into \u201chot\u201d and supporting antitumor T-cell activity, Lipo-LPS-Rg3 offers a promising strategy for MSS\/pMMR CRC immunotherapy.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1831497","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:39:05Z","timestamp":1784007545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reprogramming the immunosuppressive microenvironment in MSS\/pMMR colorectal cancer via synergistic pyroptosis induction and PD-L1 suppression"],"prefix":"10.3389","volume":"17","author":[{"given":"Jingyi","family":"Mo","sequence":"first","affiliation":[{"name":"Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weirui","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology","place":["Taipa, Macao SAR, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taikang Xianlin Drum Tower Hospital","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiong","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]},{"name":"Department of Pharmacy, Women and Children\u2019s Hospital Affiliated to Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chang","sequence":"additional","affiliation":[{"name":"Nanjing Medical University","place":["Nanjing, Jiangsu, China"]},{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut"},{"key":"B2","first-page":"735","article-title":"Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives","volume":"16","author":"Battaglin","year":"2018","journal-title":"Clin Adv Hematol Oncol H&O"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.cd-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.126","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.7.4832","article-title":"NFATc1 regulates PD-1 expression upon T cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0303-3","article-title":"Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations","volume":"37","author":"Zerdes","year":"2018","journal-title":"Oncogene"},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.09.129","article-title":"Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune","volume":"96","author":"Jiang","year":"2017","journal-title":"Biomed Pharmacot"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2017.2857","article-title":"Anticancer effects of ginsenoside Rg3","volume":"39","author":"Sun","year":"2017","journal-title":"Int J Mol Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.04.065","article-title":"Development of liposomal Ginsenoside Rg3: formulation optimization and evaluation of its anticancer effects","volume":"450","author":"Yu","year":"2013","journal-title":"Int J Pharm"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2017.1391893","article-title":"Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy","volume":"24","author":"Li","year":"2017","journal-title":"Drug Del"},{"key":"B16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","article-title":"Pyroptosis: mechanisms and diseases","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduction Tgt Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-025-02344-4","article-title":"Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives","volume":"24","author":"Huang","year":"2025","journal-title":"Mol Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature15514","article-title":"Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death","volume":"526","author":"Shi","year":"2015","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature15541","article-title":"Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling","volume":"526","author":"Kayagaki","year":"2015","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1321700111","article-title":"Guanylate binding proteins promote caspase-11\u2013dependent pyroptosis in response to cytoplasmic LPS","volume":"111","author":"Pilla","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2015.139","article-title":"Gasdermin D is an executor of pyroptosis and required for interleukin-1\u03b2 secretion","volume":"25","author":"He","year":"2015","journal-title":"Cell Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1038\/s41467-020-18443-3","article-title":"Indirect regulation of HMGB1 release by gasdermin D","volume":"11","author":"Volchuk","year":"2020","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nri1004","article-title":"Innate immune sensing and its roots: the story of endotoxin","volume":"3","author":"Beutler","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198908033210503","article-title":"The cardiovascular response of normal humans to the administration of endotoxin","volume":"321","author":"Suffredini","year":"1989","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00872-1","article-title":"The immune microenvironment of colorectal cancer","volume":"25","author":"Kennel","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1012501","article-title":"TLR agonists: our best frenemy in cancer immunotherapy","volume":"93","author":"Kaczanowska","year":"2013","journal-title":"J Leukocyte Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12943-020-01200-x","article-title":"The biomarkers of hyperprogressive disease in PD-1\/PD-L1 blockage therapy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-022-01294-4","article-title":"Exploring immunotherapy in colorectal cancer","volume":"15","author":"Weng","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz093","article-title":"Immunotherapy for colorectal cancer: a review of current and novel therapeutic approaches","volume":"111","author":"Franke","year":"2019","journal-title":"JNCI: J Natl Cancer Ins"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-1327","article-title":"Genetic mechanisms of immune evasion in colorectal cancer","volume":"8","author":"Grasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-17-3297","article-title":"NFATc1 promotes antitumoral effector functions and memory CD8+ T-cell differentiation during non\u2013small cell lung cancer development","volume":"78","author":"Heim","year":"2018","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.1240248","article-title":"Noncanonical inflammasome activation by intracellular LPS independent of TLR4","volume":"341","author":"Kayagaki","year":"2013","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nature18629","article-title":"Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature18590","article-title":"Pore-forming activity and structural autoinhibition of the gasdermin family","volume":"535","author":"Ding","year":"2016","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07373-5","article-title":"ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D","volume":"630","author":"Du","year":"2024","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrmicro2070","article-title":"Pyroptosis: host cell death and inflammation","volume":"7","author":"Bergsbaken","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.34133\/research.0545","article-title":"Protein phosphatase 2A promotes CD8+ T cell effector function through the augmentation of CD28 costimulation","volume":"8","author":"Zhu","year":"2025","journal-title":"Research"},{"key":"B43","first-page":"20240047","article-title":"NIR II-Guided Photoactivatable Silencing Polyplex Boosts Cancer Immunotherapy","volume-title":"Exploration (Beijing)","author":"Zhang","year":"2025"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.5.1250","article-title":"Lipopolysaccharide toxicity-regulating proteins in bacteremia","volume":"171","author":"Froon","year":"1995","journal-title":"J Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831497\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:39:06Z","timestamp":1784007546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831497\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2026.1831497"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1831497","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1831497"}}